Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability

Misun Cho, Eunhyun Choi, Jee Sun Yang, Chulho Lee, Jeong Jea Seo, Beom Seok Kim, Soo Jin Oh, Hwan Mook Kim, Kiho Lee, Song Kyu Park, Ho Jeong Kwon, Gyoonhee Han

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Histone deacetylases (HDACs) are important enzymes in epigenetic regulation and are therapeutic targets for cancer. Most zinc-dependent HDACs induce proliferation, dedifferentiation, and anti-apoptotic effects in cancer cells. We designed and synthesized a new series of pyridone-based HDAC inhibitors that have a pyridone ring in the core structure and a conjugated system with an olefin connecting the hydroxamic acid moiety. Consequently, most of the selected pyridone-based HDAC inhibitors showed similar or higher inhibition profiles in addition to remarkable metabolic stability against hydrolysis relative to the corresponding lactam-based HDAC inhibitors. Furthermore, the selectivity of the novel pyridine-based compounds was evaluated across all of the HDAC isoforms. One of these compounds, (E)-N-hydroxy-3-{1-[3-(naphthalen-2-yl)propyl]-2-oxo-1,2-dihydropyridin-3-yl}acrylamide, exhibited the highest level of HDAC inhibition (IC50=0.07μM), highly selective inhibition of classI HDAC1 and classII HDAC6 enzymes, metabolic stability in mouse liver microsomal studies, and effective growth inhibition of various cancer cell lines. Docking studies indicated that a long alkyl linker and bulky hydrophobic cap groups affect invitro activities. Overall, the findings reported herein regarding pyridone-based HDAC inhibitors can be used to guide future research efforts to develop new and effective anticancer therapeutics.

Original languageEnglish
Pages (from-to)272-279
Number of pages8
JournalChemMedChem
Volume8
Issue number2
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Pyridones
Histone Deacetylase Inhibitors
Histone Deacetylases
Cells
Hydroxamic Acids
Enzyme Stability
Lactams
Neoplasms
Acrylamide
Alkenes
Enzymes
Epigenomics
Liver
Inhibitory Concentration 50
Zinc
Hydrolysis
Protein Isoforms
Cell Line

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Cho, Misun ; Choi, Eunhyun ; Yang, Jee Sun ; Lee, Chulho ; Seo, Jeong Jea ; Kim, Beom Seok ; Oh, Soo Jin ; Kim, Hwan Mook ; Lee, Kiho ; Park, Song Kyu ; Kwon, Ho Jeong ; Han, Gyoonhee. / Discovery of Pyridone-Based Histone Deacetylase Inhibitors : Approaches for Metabolic Stability. In: ChemMedChem. 2013 ; Vol. 8, No. 2. pp. 272-279.
@article{29c08ff4a90d45dcb828a5a322b37ea7,
title = "Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability",
abstract = "Histone deacetylases (HDACs) are important enzymes in epigenetic regulation and are therapeutic targets for cancer. Most zinc-dependent HDACs induce proliferation, dedifferentiation, and anti-apoptotic effects in cancer cells. We designed and synthesized a new series of pyridone-based HDAC inhibitors that have a pyridone ring in the core structure and a conjugated system with an olefin connecting the hydroxamic acid moiety. Consequently, most of the selected pyridone-based HDAC inhibitors showed similar or higher inhibition profiles in addition to remarkable metabolic stability against hydrolysis relative to the corresponding lactam-based HDAC inhibitors. Furthermore, the selectivity of the novel pyridine-based compounds was evaluated across all of the HDAC isoforms. One of these compounds, (E)-N-hydroxy-3-{1-[3-(naphthalen-2-yl)propyl]-2-oxo-1,2-dihydropyridin-3-yl}acrylamide, exhibited the highest level of HDAC inhibition (IC50=0.07μM), highly selective inhibition of classI HDAC1 and classII HDAC6 enzymes, metabolic stability in mouse liver microsomal studies, and effective growth inhibition of various cancer cell lines. Docking studies indicated that a long alkyl linker and bulky hydrophobic cap groups affect invitro activities. Overall, the findings reported herein regarding pyridone-based HDAC inhibitors can be used to guide future research efforts to develop new and effective anticancer therapeutics.",
author = "Misun Cho and Eunhyun Choi and Yang, {Jee Sun} and Chulho Lee and Seo, {Jeong Jea} and Kim, {Beom Seok} and Oh, {Soo Jin} and Kim, {Hwan Mook} and Kiho Lee and Park, {Song Kyu} and Kwon, {Ho Jeong} and Gyoonhee Han",
year = "2013",
month = "2",
day = "1",
doi = "10.1002/cmdc.201200529",
language = "English",
volume = "8",
pages = "272--279",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

Cho, M, Choi, E, Yang, JS, Lee, C, Seo, JJ, Kim, BS, Oh, SJ, Kim, HM, Lee, K, Park, SK, Kwon, HJ & Han, G 2013, 'Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability', ChemMedChem, vol. 8, no. 2, pp. 272-279. https://doi.org/10.1002/cmdc.201200529

Discovery of Pyridone-Based Histone Deacetylase Inhibitors : Approaches for Metabolic Stability. / Cho, Misun; Choi, Eunhyun; Yang, Jee Sun; Lee, Chulho; Seo, Jeong Jea; Kim, Beom Seok; Oh, Soo Jin; Kim, Hwan Mook; Lee, Kiho; Park, Song Kyu; Kwon, Ho Jeong; Han, Gyoonhee.

In: ChemMedChem, Vol. 8, No. 2, 01.02.2013, p. 272-279.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discovery of Pyridone-Based Histone Deacetylase Inhibitors

T2 - Approaches for Metabolic Stability

AU - Cho, Misun

AU - Choi, Eunhyun

AU - Yang, Jee Sun

AU - Lee, Chulho

AU - Seo, Jeong Jea

AU - Kim, Beom Seok

AU - Oh, Soo Jin

AU - Kim, Hwan Mook

AU - Lee, Kiho

AU - Park, Song Kyu

AU - Kwon, Ho Jeong

AU - Han, Gyoonhee

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Histone deacetylases (HDACs) are important enzymes in epigenetic regulation and are therapeutic targets for cancer. Most zinc-dependent HDACs induce proliferation, dedifferentiation, and anti-apoptotic effects in cancer cells. We designed and synthesized a new series of pyridone-based HDAC inhibitors that have a pyridone ring in the core structure and a conjugated system with an olefin connecting the hydroxamic acid moiety. Consequently, most of the selected pyridone-based HDAC inhibitors showed similar or higher inhibition profiles in addition to remarkable metabolic stability against hydrolysis relative to the corresponding lactam-based HDAC inhibitors. Furthermore, the selectivity of the novel pyridine-based compounds was evaluated across all of the HDAC isoforms. One of these compounds, (E)-N-hydroxy-3-{1-[3-(naphthalen-2-yl)propyl]-2-oxo-1,2-dihydropyridin-3-yl}acrylamide, exhibited the highest level of HDAC inhibition (IC50=0.07μM), highly selective inhibition of classI HDAC1 and classII HDAC6 enzymes, metabolic stability in mouse liver microsomal studies, and effective growth inhibition of various cancer cell lines. Docking studies indicated that a long alkyl linker and bulky hydrophobic cap groups affect invitro activities. Overall, the findings reported herein regarding pyridone-based HDAC inhibitors can be used to guide future research efforts to develop new and effective anticancer therapeutics.

AB - Histone deacetylases (HDACs) are important enzymes in epigenetic regulation and are therapeutic targets for cancer. Most zinc-dependent HDACs induce proliferation, dedifferentiation, and anti-apoptotic effects in cancer cells. We designed and synthesized a new series of pyridone-based HDAC inhibitors that have a pyridone ring in the core structure and a conjugated system with an olefin connecting the hydroxamic acid moiety. Consequently, most of the selected pyridone-based HDAC inhibitors showed similar or higher inhibition profiles in addition to remarkable metabolic stability against hydrolysis relative to the corresponding lactam-based HDAC inhibitors. Furthermore, the selectivity of the novel pyridine-based compounds was evaluated across all of the HDAC isoforms. One of these compounds, (E)-N-hydroxy-3-{1-[3-(naphthalen-2-yl)propyl]-2-oxo-1,2-dihydropyridin-3-yl}acrylamide, exhibited the highest level of HDAC inhibition (IC50=0.07μM), highly selective inhibition of classI HDAC1 and classII HDAC6 enzymes, metabolic stability in mouse liver microsomal studies, and effective growth inhibition of various cancer cell lines. Docking studies indicated that a long alkyl linker and bulky hydrophobic cap groups affect invitro activities. Overall, the findings reported herein regarding pyridone-based HDAC inhibitors can be used to guide future research efforts to develop new and effective anticancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84873805830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873805830&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201200529

DO - 10.1002/cmdc.201200529

M3 - Article

C2 - 23292995

AN - SCOPUS:84873805830

VL - 8

SP - 272

EP - 279

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 2

ER -